Giuliano Amato
Giuliano Amato
The SARS-CoV-2 pandemic has clearly drawn attention to the shortcomings and flaws of the healthcare systems not just of low- and middle-income countries but also of high-income countries proudly proclaiming themselves "welfare societies". T...
[To transplant or not to transplant after CAR-T: that is the question!] [0.03%]
[移植还是不移植CAR-T后：这是一个问题！]
Luca Tosoni,Antonella Geromin,Francesca Patriarca
Luca Tosoni
CAR-T cell therapy revolutioned the therapeutic landscape of the relapsed/refractory B-cell acute lymphoblastic leukemia (ALL-R/R), improving relapse-free survival and overall survival of patients. Optimal management of late complications, ...
[A clinical experience with CAR-T cell therapy brexu-cel as salvage option for a Relapsed/Refractory patient with B-Cell Acute Lymphoblastic Leukemia in advanced disease stage] [0.03%]
一例复发/难治性B细胞急性淋巴细胞白血病患者接受CAR-T细胞治疗（brexucabtagene autoleucel）的临床体会
Jacopo Nanni,Federica Ardizzoia
Jacopo Nanni
Brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is a promising and available salvage option for relapsed/refractory philadelphia-positive B-Cell Acute Lymphoblastic Leukemia patients, p...
[CAR-T therapy in relapsed or refractory B-cell acute lymphoblastic leukemia: a new treatment paradigm] [0.03%]
[B细胞急性淋巴细胞白血病复发和难治性治疗的CAR-T疗法——新治疗模式]
Giovanni Grillo,Anna Mochi
Giovanni Grillo
The therapy of patients with acute lymphoblastic leukemia (ALL) in the latter has achieved significant progress by increasing the complete remission (CR) rate, re-binding allogeneic transplantation to patients with high-risk disease and/or ...
[Case of brexu-cel at first relapse in an elderly patient] [0.03%]
老年患者复发难治性多发性骨髓瘤应用brexucabtagene autoleucel治疗的病例报告
Marco Cerrano,Lorenzo Celona,Giulia Berutto et al.
Marco Cerrano et al.
Introduction: Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) represents a complex clinical scenario, and the advent of immunotherapy has radically changed the therapeutic options available for thes...
[Brexu-cel cell therapy and subsequent allogeneic hematopoietic stem cell transplantation in the treatment of late-relapse B-cell acute lymphoblastic leukemia] [0.03%]
Brexucell治疗晚发性复发B细胞急性淋巴细胞白血病及随后异基因造血干细胞移植
Lucia Brunello
Lucia Brunello
Here we report the case of a 39 years old patient who experienced a hematological relapse of B-cell acute lymphoblastic leukemia 23 months after completion of maintenance therapy. Relapse occurred two days after brexu-cel approval for reimb...
Terapia della leucemia linfoblastica acuta dell’adulto con cellule CAR-T [0.03%]
成人急性淋巴细胞白血病CAR-T细胞治疗
Alessandro Rambaldi
Alessandro Rambaldi